sgusers5的部落格

NEW YORK, Jan.24小時迷你倉 6, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Translational Regenerative Medicine: Market Prospects 2014-2024 .reportlinker.com/p0595030/Translational-Regenerative-Medicine-Market-Prospects-2014-2024.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_TransplantationReport DetailsOur new study shows you the commercial potential of regenerative treatmentsWhat does the future hold for regenerative medicine? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.Our study lets you assess regenerative medicine: cell-based therapies that aim to restore function and regenerate diseased tissues. It lets you assess projected sales at world market, market segment, product and regional level to 2024. You will see financial results, interviews, trends, opportunities, and revenue predictions.In our investigation you also see qualitative analyses, news R&D and business developments. Our 240 page report provides 122 tables, charts, and graphs. Read the full transcripts of three exclusive expert opinion interviews from leading industry specialists informing your understanding and allowing you to assess prospects for investments and sales:- Dr. Alan Trounson - President, California Institute for Regenerative Medicine (CIRM)- Professor Francois Berthiaume - Associate Professor of Biomedical Engineering, Rutgers University, New Jersey- Dr. William Dolphin - CEO, Avita MedicalYou will find prospects for submarkets and productsIn addition to analyses of the overall world market, you will see revenue forecasting of three world-level submarkets to 2024:-- Stem cell therapy-- Tissue engineered products-- Gene therapyAlso, you will discover how leading products - including Apligraf, Dermagraft, ReCell, Osteocel Plus, Trinity Evolution and Neovasculgen - perform from 2014 to 2024. You will find business research and analysis with individual revenue forecasts and discussions.What are the prospects in leading regions and countries?There are many commercial opportunities in developed and developing countries. You discover individual revenue forecasts to 2024 for regions, with discussions of countries:-- US-- Europe-- Asia Pacific - including Japan, China, India, South Korea and Australia-- Rest of the world - including BrazilThis decade, revenues from the Asia-Pacific region will be the fastest-growing worldwide.Revenues in many countries will multiply many times from 2014 to 2024, our analyses show.Research and development - potential in this emerging industryWhat's happening in the R&D pipeline for translational regenerative medicine? Our study shows developmental trends:-- Diabetes treatments-- Cardiovascular and cardiology treatments-- Cancer therapy-- Ocular (ophthalmological) uses - treating eye diseases-- Wound care-- Treatments for neurological disordersDiscover how science and technology is changing translational regenerative medicine. Our investigation shows you trends and outlooks, exploring matters affecting the sector.What issues affect the regenerative treatments and industry market?Our study lets you assess industry trends and outlooks. You will find discussions, including qualitative analyses:-- Tissue engineering - including 3D bioprinting and organ transplants-- Autologous chondrocyte implantation (ACI)-- Haematopoietic stem cell transplantation and other cellular treatments-- Orthobiologics, biomaterials, neuroprotection and nanotechnology-- Gene therapy, including delivery and viral vectors-- Bone marrow material and human embryonic stem cells-- Mesenchymal stem cell technologies-- Skin regeneration, wound repair, cosmetic uses and treating degenerative disorders-- Treatment of leg ulcers, cartilage, livers, hearts and eyesYou will see discussions of technological, commercial, and economic matters, with emphasis on organisations developing technologies.Leading companies and potential for market growthThis decade, this biotechnology sector will flourish - already there are products on sale and a myriad of clinical trials underway.The R&D pipeline is strong and promising. Visiongain expects high demand for treatments, with degenerative diseases, wound healing, and other applications stimulating progress.Our work shows you what products and organisations hold greatest potential. See profiles of 18 leading companies, including these:-- Advanced Cell Technology-- Anterogen-- Genzyme-- Mesoblast-- NuVasive-- Organogenesis-- Osiris Therapeutics-- Shire Regenerative Medicine-- TiGenix-- UniQure-- Alphatec Spine-- Avita MedicalIn general, a company profile gives you the following information-- Discussion of a company's activities and outlook-- Recent financial results-- Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations.-- Analysis of current clinical trial activity-- Insight into pipeline products in developmentDiscover capabilities, progress, and commercial prospects, helping you stay ahead. What effects will improved regulatory processes have? Advances in stem cell science and an evolving patent landscape will change the industry.How the Translational Regenerative Medicine: Market Prospects 2014-2024 report helps youIn summary, our 240 page report gives you the following knowledge:-- Revenues forecasts to 2024 for the overall world regenerative medicine market and 3 submarkets - discover that industry's prospects, finding promising places for investments and revenues-- Potential revenues of leading regenerative medicine products and portfolios to 2024-- Assessment of 18 leading companies, and others, discovering activities and outlooks-- Market forecasting to 2024 for leading regions - US, Europe, and Asia-Pacific-- Review of the late-stage product pipeline by market segment and therapeutic area-- View opinions from our survey, seeing interviews with authorities-- Investigation of competition and opportunities influencing sales-- Discussion of what stimulates and restrains the industry and marketYou will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.Information found nowhere elseWith our survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.1. Executive Summary1.1 Overview of Findings1.2 Structure of the Report1.3 Research and Analysis Methods1.4 Glossary of Terms in this Report2. Introduction to Translational Regenerative Medicine2.1 What is Translational Regenerative Medicine?2.2 Translational Regenerative Medicine: Market Segmentation2.2.1 Stem Cell Therapy2.2.1.1 Classifying Stem Cells by Potency2.2.1.2 Categories of Stem Cells2.2.1.3 Autologous versus Allogeneic Stem Cells: Towards Universal Stem Cell Products?2.2.1.4 Stem Cell Therapeutic Applications2.2.2 Tissue Engineering2.2.3 Gene Therapy2.2.3.1 Harnessing Infectivity: Viral Vectors in Gene Therapy2.3 Other Areas of Regenerative Medicine2.3.1 Small Molecules and Proteins - Enhancing Regenerative Medicine2.3.2 Cosmetic Applications of Regenerative Medicine2.4 Regulation of Regenerative Medicine2.4.1 Regulation of Regenerative Medicine Products in Europe2.4.2 Regulation of Regenerative Medicine Products in the US2.5 Phases of Clinical Trials2.6 Scope of this Report2.6.1 Products Excluded from this Report3. Regenerative Medicine: World Market 2014-20243.1 The World Regenerative Medicine Market in 2012 and 20133.2 Leading Regenerative Medicine Products3.3 Leading Companies in the Regenerative Medicine Market3.4 World Regenerative Medicine Market: Sales Forecast 2014-20243.4.1 Regenerative Medicine Market Segments: Sales Forecasts 2014-20243.4.2 Regenerative Medicine: CAGRs by Segment 2014-20243.4.3 Changing Market Shares by Segment 2014-20243.5 Stem Cell Therapies Lead the Regenerative Medicine Market3.5.1 Stem Cells Therapy Market: Drivers and Restraints 2014-20243.6 Tissue Engineered Products Will Continue Strong Growth3.6.1 Tissue Engineered Products Market: Drivers and Restraints 2014-20243.7 Gene Therapies Show High Growth Potential3.7.1 Gene Therapy Market: Drivers and Restraints 2014-20244. Leading National Markets 2014-20244.1 Regional Breakdown of the World Regenerative Medicine Market4.2 World Regenerative Medicine Market: Regional Forecast 2014-20244.2.1 Regenerative Medicine: CAGRs by Regional Market 2014-20244.2.2 How Will Regional Market Shares Change to 2024?4.3 The US Regenerative Medicine Market 2014-20244.3.1 US Regenerative Medicine Market: Drivers and Restraints4.3.2 US Market Overview: The Leading Regenerative Medicine Market4.3.2.1 Regulation of Regenerative Medicine in the US4.3.2.2 Embryonic Stem Cell Research Remains Controversial4.3.2.3 An End to Patents on Human Genes?4.4 The European Regenerative Medicine Market 2014-20244.4.1 European Regenerative Medicine Market: Drivers and Restraints4.4.2 European Market Overview: A Strong Science Base4.4.2.1 On the Brink of a Unitary European Patent System4.4.2.2 Regulation of Regenerative Medicine in Europe4.4.2.3 European REMEDiE Project4.4.2.4 A UK Perspective on the Regenerative Medicine Market4.4.2.5 Developments in the Russian Regenerative Medicine Market4.5 The Asia-Pacific Regenerative Medicine Market 2014-20244.5.1 Asia-Pacific Regenerative Medicine Market: Drivers and Restraints4.5.2 Asia-Pacific Market Overview: Towards Rapid Commercialisation4.5.2.1 Japan: Transforming the Regulatory Landscape4.5.2.2 China: Encouraging Stem Cell R&D4.5.2.3 India: An Emerging RM Industry4.5.2.4 South Korea: First to Approve Stem Cell Treatments4.5.2.5 Australia: Encouraging Translational Regenerative Medicine4.6 The Regenerative Medicine Market in the Rest of the World 2014-20244.6.1 Brazil - An Emerging Market in South America5. Leading Companies in the Regenerative Medicine Market5.1 Aastrom Biosciences: Developing Cardiovascular Stem Cell Therapies5.1.1 Aastrom Biosciences: Clinical Trials5.1.2 Aastrom Biosciences: Products in Development5.1.2.1 Ixmyelocel-T: Autologous Mesenchymal Stem Cell Therapy5.2 Advanced Cell Technology: Stem Cells for Eye Diseases5.2.1 Advanced Cell Technology: Clinical Trials5.2.2 Advanced Cell Technology: Products in Development5.2.2.1 Retinal Pigment Epithelial Cell Therapy5.2.2.2 iPSC-derived Platelets5.2.2.3 Hemangioblast Program5.2.2.4 Mesenchymal Stem Cell Program5.2.2.5 Other Products5.3 Alphatec Spine: Bone Allgrafts5.3.1 Alphatec Spine: Clinical Trials5.3.2 Alphatec Spine: Products in Development5.4 Anterogen: South Korean Stem Cell Company5.4.1 Anterogen: Clinical Trials5.4.2 Anterogen: Products in Development5.5 Athersys: Developing Allogeneic Progenitor Cell Therapy5.5.1 Athersys: Clinical Trials5.5.2 Athersys: Products in Development5.5.2.1 MultiStem: Allogeneic Multipotent Adult Progenitor Cells5.5.2.2 Serotonin Receptor Agonists5.6 Avita Medical: Spray-On Skin Cell Therapy5.6.1 Avita Medical: Clinical Trials5.7 AxoGen: Nerve Regeneration Products5.7.1 AxoGen: Clinical Trials5.7.2 AxoGen: Products in Development5.8 Genzyme (acquired by Sanofi): A Leader in Regenerative Medicine5.8.1 Genzyme: Clinical Trials5.8.2 Genzyme: Products in Development5.9 Medipost: Cartilage Repair with Cartistem5.9.1 Medipost: Clinical Trials5.9.2 Medipost: Products in Development5.10 Mesoblast: An Australian RM Leader5.10.1 Mesoblast : Clinical Trials5.10.2 Mesoblast: Products in Development5.10.2.1 NeoFuse5.10.2.2 Prochymal5.10.2.3 Chondrogen5.10.2.4 Mesenchymal Precursor Cells in Congestive Heart Failure5.10.2.5 Other Pipeline Products5.11 NuVasive: Spinal Surgery Bone Allografts5.11.1 NuVasive: Clinical Trials5.11.2 NuVasive: Products in Development5.12 Organogenesis: a Tissue Engineering Pioneer5.12.1 Organogenesis: Clinical Trials5.12.2 Organogenesis: Products in Development5.13 Osiris Therapeutics: a Leading Stem Cell Company5.13.1 Osiris Therapeutics: Clinical Trials5.13.2 Osiris Therapeutics: Products in Development5.14 Pharmicell: South Korean Stem Cell Leader5.14.1 Pharmicell: Clinical Trials5.14.2 Pharmicell: Products in Development5.15 Regenerys: Manufacturing Skin Substitutes5.15.1 Regenerys: Clinical Trials5.15.2 Regenerys: Products in Development5.16 Shire Regenerative Medicine: Entering the RM Market5.16.1 Shire: Clinical Trials5.16.2 Shire: Products in Development5.16.2.1 Vascugel5.17 TiGenix: European Cell Therapy Leader5.17.1 TiGenix: Clinical Trials5.17.2 TiGenix: Products in Development5.18 UniQure: First Gene Therapy Approved in Europe5.18.1 UniQure: Clinical Trials5.18.2 UniQure: Products in Development6. Stem Cell Therapy: Leading Applications 2014-20246.1 Stem Cell Therapy: Currently Available Therapies6.1.1 Haematopoietic Stem Cell Transplantation (HSCT)6.1.2 Stem Cell Orthobiologics6.1.2.1 Osteocel Plus (NuVasive): Sales Forecast 2014-20246.1.2.2 Trinity ELITE and Trinity Evolution (Orthofix): Sales Forecast 2014-20246.1.2.3 LiquidGen (Skye Orthobiologics)6.1.2.4 AlloStem (AlloSource)6.1.2.5 PureGen (AlphaTec Spine)6.1.3 Other Approved Stem Cell Therapy Products6.1.3.1 Prochymal (remestemcel-L, Osiris Therapeutics/Mesoblast): Sales Forecast 2014-20246.1.3.2 Hearticellgram-AMI (Pharmicell)6.1.3.3 Cupistem (Anterogen)6.1.3.4 Cartistem (Medipost)6.2 Stem Cell Therapy Pipeline to 20246.2.1 Late-Stage Pipeline for Stem Cell Therapies6.2.1.1 StemEx (carlecortemcel-L, Gamida Cell)6.2.1.2 Mesenchymal Precursor Cell Therapies (Mesoblast)6.2.1.3 Adult Autologous CD34+ Cells (Baxter)6.2.1.4 MyoCell (Bioheart)6.2.1.5 Cx601 (TiGenix)6.2.1.6 Adipose-Derived Stem Cells (Cytori Therapeutics)6.2.1.7 Stempeucel (Stempeutics Research)6.2.1.8 C-Cure (Cardio3 BioSciences)6.2.1.9 Other Late-Stage Stem Cell Therapies6.2.2 Diabetes and Stem Cell Therapy6.2.2.1 Mesenchymal Precursor Cells (Mesoblast)6.2.2.2 VC-01 (ViaCyte)6.2.3 Cardiovascular Disease and Stem Cell Therapy6.2.3.1 Endometrial Regenerative Cells (Medistem)6.2.3.2 AMR-001 (NeoStem)6.2.3.3 CAP-1002 (Capricor)6.2.4 Stem Cell Therapy in Cancer6.2.4.1 CLT-008 (Cellerant Therapeutics)6.2.4.2 OncoCyte/BioTime - Targeting Cancer with Gene and Stem Cell Therapy6.2.5 Stem Cell Therapy for CNS Conditions6.2.5.1 NurOwn (BrainStorm Cell Therapeutics)6.2.5.2 NSI-566 (Neuralstem)6.2.5.3 MultiStem (Athersys)6.2.5.4 PDA-001 (cenplacel-L, Celgene)6.2.5.5 ALD-401 (Cytomedix)6.2.5.6 ReN001 (ReNeuron)6.2.6 Stem Cell Therapy for Eye Diseases6.2.6.1 MA09-hRPE (Advanced Cell Technology)6.2.6.2 HuCNS-SC (StemCells, Inc.)6.2.6.3 EC200 (EyeCyte)6.2.6.4 Pfizer's Collaboration with The London Project to Cure Blindness7. Tissue Engineering: Leading Applications 2014-20247.1 Tissue Engineering: Currently Available Therapies7.1.1 Tissue Engineering for Wound Repair7.1.1.1 Apligraf (Organogenesis): Sales Forecast 2014-20247.1.1.2 BioDfence and BioDfactor (BioD)7.1.1.3 CureXcell (MacroCure)7.1.1.4 Dermagraft (Shire): Sales Forecast 2014-20247.1.1.5 Epicel (Sanofi)7.1.1.6 Grafix (Osiris Therapeutics)7.1.1.7 MySkin and CyroSkin (Regenerys)7.1.1.8 ReCell (Avita Medical): Sales Forecast 2014-20247.1.2 Tissue Engineering for Cartilage Repair: Autologous Chondrocyte Implantation7.1.2.1 Carticel (Sanofi)7.1.2.2 ChondroCelect (TiGenix)7.1.2.3 DeNovo NT (Zimmer)7.1.2.4 MACI (Sanofi)7.1.3 Other Available Tissue Engineering Therapies7.1.3.1 Autologous Cultured Cell and Tissue Products (Japan Tissue Engineering Co.)7.1.3.2 Gintuit (Organogenesis)7.1.3.3 LAVIV (azficel-T, Fibrocell Science)7.1.3.4 Acellular Tissue Engineering Products7.2 Tissue Engineering Pipeline to 20247.2.1 Autologous Chondrocyte Implantation Pipeline7.2.2 Tissue Engineering for Skin7.2.3 Tissue Engineering for Liver Disease7.2.3.1 Extracorporeal Bio-Artificial Liver Therapy (Vital Therapies)7.2.4 Tissue Engineering for Cardiovascular Disease7.2.5 Tissue Engineering for Eye Diseases7.2.6 Prospects for Organ Transplantation8. Gene Therapy: Leading Applications 2014-20248.1 Gene Therapy: Currently Available Therapies8.1.1 Gendicine (Benda Pharmaceutical)8.1.2 Oncorine (Shanghai Sunway Biotech)8.1.3 Neovasculgen (Human Stem Cells Institute)8.1.4 Neovasculgen (HSCI): Sales Forecast 2014-20248.1.5 Glybera (UniQure)8.2 Withdrawn From Sale: Rexin-G (Epeius Biotechnologies)8.3 Gene Therapy Pipeline to 20248.3.1 Late-Stage Gene Therapy Pipeline8.3.1.1 Collategene (beperminogene perplasmid, AnGes MG/Vical)8.3.1.2 ProstAtak (AdV-tk, Advantagene)8.3.1.3 Trinam (taberminogene vadenovec, Ark Therapeutics)8.3.1.4 TVEC (talimogene laherparepvec, Amgen)8.3.1.5 AAV2-hRPE65v2 (Spark Therapeutics)8.3.1.6 CG0070 (Cold Genesys)8.3.2 Gene Therapy for Diabetes8.3.3 Gene Therapy for Cancer8.3.4 Gene Therapy for Neurological Diseases8.3.5 Gene Therapy for Haemophilia B9. Qualitative Analysis of the Regenerative Medicine Market 2014-20249.1 SWOT Analysis of the Regenerative Medicine Market9.2 Strengths9.2.1 Incremental Progress in Research9.2.2 Regulatory Frameworks Improving9.2.3 An Established Route to Market9.2.4 Strong Support from National Governments9.3 Weaknesses9.3.1 Lack of Venture Capital9.3.2 High Costs of RM Therapies9.3.3 Commercialisation Requires New Business Models9.3.4 Lack of Standardisation9.4 Opportunities9.4.1 Disruptive RM Therapies Can Create New Markets9.4.2 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up9.4.3 Incre迷你倉旺角sing Burden of Chronic Disease9.4.4 Medical Tourism Can Drive the Market9.5 Threats9.5.1 Restraints on Reimbursement9.5.2 Difficulty Establishing an Evidence Base9.5.3 Ethical Concerns Limiting R&D9.5.4 Progress May be Slow9.6 Porter's Five Forces Analysis of the Regenerative Medicine Market9.6.1 Rivalry Among Competitors [Medium]9.6.2 Threat of New Entrants [Medium]9.6.3 Power of Suppliers [Low]9.6.4 Power of Buyers [Low]9.6.5 Threat of Substitutes [High]10. Research Interviews10.1 Interview with Dr Alan Trounson, President, California Institute for Regenerative Medicine (CIRM)10.1.1 Improved Funding in the Stem Cells Field10.1.2 MSCs: Major Potential or Merely a Placeholder?10.1.3 CIRM Investment Strategies10.1.4 The Changing Regulatory Environment Worldwide10.1.5 Key Trends for the Next Five to Ten Years10.2 Interview with Professor Francois Berthiaume, Associate Professor of Biomedical Engineering, Rutgers University, New Jersey10.2.1 On the Regenerative Medicine Market10.2.2 On the Future of Stem Cell Therapies10.2.3 Challenges in the Tissue Engineering Market10.2.4 Thoughts on Future Developments10.3 Interview with Dr William Dolphin, CEO, Avita Medical, UK10.3.1 Future Prospects for the Regenerative Medicine Market10.3.2 Is Regenerative Medicine Ready For Commercialisation?10.3.3 On Emerging Regenerative Medicine Markets10.3.4 Future Therapeutic Areas10.3.5 Barriers to Developing Regenerative Medicine?10.3.6 Thoughts on Future Developments11. Conclusions11.1 The World Regenerative Medicine Market in 2012 and 201311.1.1 Current Leading Regenerative Medicine Segments11.1.2 Leading Regenerative Medicine Products11.1.3 Leading Regenerative Medicine Companies11.1.4 Leading Regional Markets11.2 World Regenerative Medicine Market Forecast 2014-202411.3 Regenerative Medicine Late-Stage Pipeline11.4 The Future of the Regenerative Medicine Market?List of TablesTable 1.1 Currency Exchange Rates, 2012Table 2.1 European Union Definitions of Regenerative Medicine Products, 2013Table 2.2 Potency and Source of Stem Cells, 2013Table 2.3 Germ Layers and Their Associated Cells, Tissues and Organs, 2013Table 2.4 Stem Cell Categories, 2013Table 2.5 Stem Cell Donor Terminology, 2013Table 2.6 Clinical Trial PhasesTable 3.1 World Regenerative Medicine Market: Revenues ($m) and Market Shares (%) by Segment, 2012Table 3.2 Leading Regenerative Medicine Products: Revenues ($m), 2012Table 3.3 Leading Companies in the Regenerative Medicine Market: Leading Products and Net Revenues ($m), 2012Table 3.4 World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024Table 3.5 World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2012-2018Table 3.6 World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2018-2024Table 3.7 World Regenerative Medicine Market: CAGR (%) by Segment, 2012-2018, 2018-2024 and 2012-2024Table 3.8 Market Shares (%) of the Regenerative Medicine Market by Segment, 2012, 2018 and 2024Table 3.9 Stem Cell Market: Revenues ($m) and Market Shares (%) by Subsegment, 2012Table 3.10 Stem Cell Therapy Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024Table 3.11 Tissue Engineered Products Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024Table 3.12 Gene Therapy Market: Commercial-Stage Products, 2013Table 3.13 Gene Therapy Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024Table 3.14 Gene Therapy Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Product, 2012-2024Table 4.1 World Regenerative Medicine Market: Revenues ($m) and Market Shares (%) by Region, 2012Table 4.2 World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Region, 2012-2018Table 4.3 World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Region, 2018-2024Table 4.4 World Regenerative Medicine Market: CAGR (%) by Region, 2012-2018, 2018-2024 and 2012-2024Table 4.5 Market Shares (%) of the Regenerative Medicine Market by Region in 2012, 2018 and 2024Table 4.6 US Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024Table 4.7 European Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024Table 4.8 Asia-Pacific Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024Table 4.9 Rest of the World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024Table 5.1 Aastrom Biosciences: Regenerative Medicine Clinical Trials, 2013Table 5.2 Advanced Cell Technology: Regenerative Medicine Clinical Trials, 2013Table 5.3 AlphaTec Spine: Regenerative Medicine Clinical Trials, 2013Table 5.4 Anterogen: Regenerative Medicine Clinical Trials, 2013Table 5.5 Athersys: Regenerative Medicine Clinical Trials, 2013Table 5.6 Avita Medical: Regenerative Medicine Clinical Trials, 2013Table 5.7 AxoGen: Regenerative Medicine Clinical Trials, 2013Table 5.8 Genzyme: Products in the US Market, 2013Table 5.9 Genzyme: Regenerative Medicine Clinical Trials, 2013Table 5.10 Medipost: Regenerative Medicine Clinical Trials, 2013Table 5.11 Mesoblast: Regenerative Medicine Clinical Trials, 2013Table 5.12 NuVasive: Regenerative Medicine Clinical Trials, 2013Table 5.13 Organogenesis: Regenerative Medicine Clinical Trials, 2013Table 5.14 Osiris Therapeutics: Regenerative Medicine Clinical Trials, 2013Table 5.15 Pharmicell: Regenerative Medicine Clinical Trials, 2013Table 5.16 Regenerys: Regenerative Medicine Clinical Trials, 2013Table 5.17 Shire: Regenerative Medicine Clinical Trials, 2013Table 5.18 TiGenix: Regenerative Medicine Clinical Trials, 2013Table 5.19 UniQure: Regenerative Medicine Clinical Trials, 2013Table 6.1 Selected Currently Available Stem Cell Products, 2013Table 6.2 FDA-Approved Cord Blood-Derived Stem Cell Products for HSCT, 2013Table 6.3 Stages of Osteogenesis, 2013Table 6.4 NuVasive: Osteocel Plus Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024Table 6.5 Orthofix: Trinity ELITE Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024Table 6.6 Mesoblast: Prochymal Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024Table 6.7 Stem Cell Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2013Table 7.1 Selected Currently Available Tissue Engineering Products, 2013Table 7.2 Organogenesis: Apligraf Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024Table 7.3 Shire: Dermagraft Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024Table 7.4 Avita Medical: ReCell Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024Table 7.5 Vital Therapies: Extracorporeal Bio-Artificial Liver Therapy Clinical Trials, 2013Table 8.1 Currently Available Gene Therapies, 2013Table 8.2 Benda Pharmaceutical: Gendicine Clinical Trials, 2013Table 8.3 Human Stem Cells Institute: Neovasculgen Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024Table 8.4 UniQure: Glybera Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024Table 8.5 Gene Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2013Table 8.6 Advantagene: Gene Therapy Clinical Trials, 2013Table 8.7 Amgen: TVEC Clinical Trials, 2013Table 8.8 Spark Therapeutics: AAV2-hRPE65v2 Clinical Trials, 2013Table 9.1 SWOT Analysis of the Regenerative Medicine Market, 2014-2024Table 9.2 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2013-2024List of FiguresFigure 2.1 Brief History of Stem Cell Research, 1900-2000Figure 2.2 Brief History of Tissue Engineering, 1900-2013Figure 2.3 Examples of FDA-Approved Tissue Engineered ProductsFigure 2.4 Brief History of Gene Therapy, 1970-2013Figure 3.1 World Regenerative Medicine Market: Market Shares (%) by Segment, 2012Figure 3.2 Leading Regenerative Medicine Products: Market Shares (%), 2012Figure 3.3 World Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024Figure 3.4 World Regenerative Medicine Market Forecast: Revenues ($m) by Segment, 2012-2024Figure 3.5 World Regenerative Medicine Market Forecast: CAGR (%) by Segment, 2012-2018Figure 3.6 World Regenerative Medicine Market Forecast: CAGR (%) by Segment, 2018-2024Figure 3.7 World Regenerative Medicine Market Forecast: CAGR (%) by Segment, 2012-2024Figure 3.8 World Regenerative Medicine Market: Market Shares (%) by Segment, 2018Figure 3.9 World Regenerative Medicine Market: Market Shares (%) by Segment, 2024Figure 3.10 Stem Cell Market: Market Shares (%) by Subsegment, 2012Figure 3.11 Stem Cell Therapy Market Forecast: Revenues ($m), 2012-2024Figure 3.12 Stem Cell Therapy Market: Drivers and Restraints, 2014-2024Figure 3.13 Tissue Engineered Products Market Forecast: Revenues ($m), 2012-2024Figure 3.14 Tissue Engineered Products Market: Drivers and Restraints, 2014-2024Figure 3.15 Gene Therapy Market Forecast: Revenues ($m), 2012-2024Figure 3.16 Gene Therapy Market: Market Shares (%) by Product, 2012Figure 3.17 Gene Therapy Market: Market Shares (%) by Product, 2018Figure 3.18 Gene Therapy Market: Market Shares (%) by Product, 2024Figure 3.19 Gene Therapy Market: Drivers and Restraints, 2014-2024Figure 4.1 World Regenerative Medicine Market: Revenues ($m) by Region, 2012Figure 4.2 World Regenerative Medicine Market: Market Shares (%) by Region, 2012Figure 4.3 World Regenerative Medicine Market Forecast: Revenues ($m) by Region, 2012-2024Figure 4.4 World Regenerative Medicine Market Forecast: CAGR (%) by Region, 2012-2018Figure 4.5 World Regenerative Medicine Market Forecast: CAGR (%) by Region, 2018-2024Figure 4.6 World Regenerative Medicine Market Forecast: CAGR (%) by Region, 2012-2024Figure 4.7 World Regenerative Medicine Market: Market Shares (%) by Region, 2018Figure 4.8 World Regenerative Medicine Market: Market Shares (%) by Region, 2024Figure 4.9 US Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024Figure 4.10 US Regenerative Medicine Market: Drivers and Restraints, 2014-2024Figure 4.11 European Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024Figure 4.12 European Regenerative Medicine Market: Drivers and Restraints, 2014-2024Figure 4.13 Asia-Pacific Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024Figure 4.14 Asia-Pacific Regenerative Medicine Market: Drivers and Restraints, 2014-2024Figure 4.15 Rest of the World Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024Figure 6.1 NuVasive: Osteocel Plus Revenue Forecast ($m), 2012-2024Figure 6.2 Orthofix: Trinity ELITE Revenue Forecast ($m), 2012-2024Figure 6.3 Mesoblast: Prochymal Revenue Forecast ($m), 2012-2024Figure 7.1 Organogenesis: Apligraf Revenue Forecast ($m), 2012-2024Figure 7.2 Shire: Dermagraft Revenue Forecast ($m), 2012-2024Figure 7.3 Avita Medical: ReCell Revenue Forecast ($m), 2012-2024Figure 8.1 Human Stem Cells Institute: Neovasculgen Revenue Forecast ($m), 2012-2024Figure 8.2 UniQure: Glybera Revenue Forecast ($m), 2012-2024Figure 9.1 World 65+ Population Forecast: Size (m), 2013-2024Figure 9.2 Porter's Five Forces Analysis of the Regenerative Medicine Market, 2014-2024Figure 11.1 World Regenerative Medicine Market: Revenues ($m) by Segment, 2012Figure 11.2 World Regenerative Medicine Market: Revenues ($m) by Region, 2012Figure 11.3 World Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024Companies ListedAastrom BiosciencesAdiposet Ltd (merged into Regenerys)Advanced BioHealing (acquired by Shire)Advanced Cell Technology (ACT)Advanced Tissue Sciences (ATS)AdvantageneAllosourceAlphaTec SpineAltrika (acquired by Regenerys)AmedicaAmgenAmorcyte (acquired by NeoStem)Amorepacific CorporationAmsterdam Molecular Therapeutics (predecessor of UniQure)AnGes MGAngioblast Systems (acquired by Mesoblast)Anika TherapeuticsAnorMED (acquired by Genzyme)Anterogen (subsidiary of Bukwang Pharm Co Ltd)Arcarios B.V.Ark TherapeuticsArteriocyteAthersysAvita MedicalAxoGenAxoGen Corporation (merged into AxoGen)Baxter InternationalBeike BiotechnologyBenda PharmaceuticalBioDBioheartBioMed Realty Trust, Inc.BioSante PharmaceuticalsBioTimeBioTissueBioVex Group (acquired by Amgen)Blackstone Medical (acquired by Orthofix)Bluebird BioBrainStorm Cell Therapeutics Inc.Bukwang Pharm Co LtdCalifornia Stem CellCapricorCardio3 BioSciencesCDICelgeneCell TargetingCellCoTecCellerant TherapeuticsCellerix (merged into TiGenix)CephalonCeregeneCHA BiotechChiesi Farmaceutici SpACiplaClinical Cell Culture (C3) (merged into Avita Medical)Clinimmune Labsco.donCold GenesysCook Biotech IncorporatedCryoCenter Saint-PetersburgCytoMedixCytori TherapeuticsDaiichi SankyoDendreonDePuy Mitek (subsidiary of Johnson & Johnson)Epeius BiotechnologiesEyeCyteFibrocell ScienceGamida Cell LtdGemabankGenpharmGenzyme (subsidiary of Sanofi)GeronHistogenicsHumacyteHuman Stem Cells InstituteInsulete IncIntrogen TherapeuticsISTO TechnologiesJapan Tissue Engineering Co. (J-TEC)JCR Pharmaceuticals Co.Johnson & JohnsonKinetic Concepts Inc. (merging into KCI)LecTec Corporation (merged into AxoGen)LifeCell (merging into KCI)Lincoln Park CapitalLonzaMacroCureMedipostMedistem (formerly Medistem Laboratories)MedtronicMesoblastMitsubishi TanabeMusculoskeletal Transplant Foundation (MTF)Myriad GeneticsMytogenNational Marrow Donor Program (NMDP) (US)NeoStemNeuralstemNew York Blood CenterNippon Zoki PharmaceuticalNuVasiveOncoCyte (subsidiary of BioTime)OrganogenesisOrganovoOristemOrthofixOrthomimetics Ltd (acquired by TiGenix)Osiris TheraeuticsOxford BioMedicaParcell LaboratoriesPervasis Therapeutics (acquired by Shire)PfizerPharmacellsPharmicell (formerly FCB-Pharmicell)Progenitor Cell Therapy (part of NeoStem)Protek GroupRegenerysReliance Life SciencesReNeuronReprobankRoslin CellabRTI SurgicalRusnanoSangamoSanofiShanghai QishengShanghai Sunway BiotechShenzhen SiBiono GeneTechShireShire Regenerative Medicine (subsidiary of Shire)Skye OrthobiologicsSotex PharmFirm (subsidiary of Protek Group)Spark TherapeuticsStemCells, Inc.Stempeutics ResearchStratatech CorporationSystagenix (merging into KCI)TCA Cellular TherapyTengionTeva Pharmaceutical Industries (Teva)TiGenixUniQureUniversity of Colorado Cord Blood BankViaCyte (formerly NovoCell)VicalVindon ScientificVisiomed Group (merged into Avita Medical)Vital Therapies, Inc.WKD Holding OyXcellerexXenetic BiosciencesZentrales Knochenmarkspender-Register Deutschland (German National Registry of Blood Stem Cell Donors) (ZKRD)ZimmerOther Organisations Mentioned in This ReportArthritis Research UKAssociazione Infermieristica per lo Studio delle Lesioni Cutanee (Nursing Association for the Study of Cutaneous Wounds) (AISLeC) (Italy)Australian Regenerative Medicine InstituteAustralian Research CouncilBeijing Cancer HospitalBoston UniversityBritish Heart FoundationCalifornia Institute of Regenerative Medicine (CIRM)Cambridge Stem Cell Biology Institute.Care Quality Commission (CQC) (UK)Catalan Institution for Research and Advanced StudiesCha General Hospital (Seoul, South Korea)Children's Hospital of PhiladelphiaChina Food and Drug Administration (CFDA, formerly SFDA)Chinese Academy of SciencesDepartment of Biotechnology (India)Department of Health (UK)Duke University School of MedicineEuropean Medicines Agency (EMA)European Patent OfficeFinnish Red Cross Blood ServiceFood and Drug Administration of the PhilippinesHarvard Medical SchoolHaute Autorite de sante (HAS) (French National Authority for Health)Health CanadaHeriot-Watt UniversityHuman Fertilisation and Embryology Authorityy (HFEA) (UK)Institute for Regenerative Medicine, Wake Forest University Baptist Medical CenterInstitute of Biomedical Research and Innovation Hospital (Kobe, Japan)International Society for Stem Cell ResearchInternet ArchiveJapan Patent OfficeJapanese Society for Regenerative MedicineKarolinska InstituteKing Fahad Medical City (Saudi Arabia)LifeSouth Community Blood CentersLondon Project to Cure BlindnessMayo ClinicMedical Research Council (UK)Medicines and Healthcare products Regulatory Agency (MHRA) (UK)Ministry of Economy, Trade and Industry (METI) (Japan)Ministry of Food and Drug Safety (MFDS, formerly KFDA) (South Korea)Ministry of Health (China)Ministry of Health, Labour and Welfare (MHLW) (Japan)Ministry of Science and Technology (China)Monash UniversityMoorfields Eye HospitalNational Health and Medical Research Council (Australia)National Institutes of Health (US)National Tissue Engineering Center (NTEC) (China)Northeast ALS consortiumPharmaceuticals and Medical Devices Agency (PMDA) (Japan)Riken Center for Developmental BiologyRussian Ministry of Healthcare and Social DevelopmentRutgers UniversitySaudi Food and Drug AuthorityScottish Centre for Regenerative MedicineSingapore General HospitalSSM Cardinal Glennon Children's Medical CenterSt. Jude's Children Research HospitalStemGenSUNY Upstate Medical UniversityUCL Institute of OphthalmologyUnited Nations' Department of Economic and Social AffairsUnited States Food and Drug Administration (FDA)Universitat Autonoma de BarcelonaUniversity College LondonUniversity of Edinburgh MRC Centre for Regenerative MedicineUniversity of MichiganUniversity of Modena Centre for Regenerative MedicineUniversity of WisconsinUS Department of DefenseVA Northern California Health Care SystemWeizmann Institute of Science (Rehovot, Israel)Wellcome TrustWorld Health OrganizationTo order this report: Translational Regenerative Medicine: Market Prospects 2014-2024 .reportlinker.com/p0595030/Translational-Regenerative-Medicine-Market-Prospects-2014-2024.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_TransplantationContact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001ReportlinkerWeb site: .reportlinker.com/mini storage